Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

CLEVELAND, Jan. 28, 2011 /PRNewswire-USNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Critical Limb Ischemia (CLI). The FDA Investigational Device Exemption (IDE 14522) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) in improving perfusion in ischemic tissue in affected limbs of patients with CLI who are not eligible for revascularization surgery.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

The Magellan technology combines a rapid bedside tissue concentration device and sterile surgical disposables that produce platelet rich plasma from blood and bone marrow aspirations in approximately 15 minutes and was FDA approved through the 510(k) process for use as deemed appropriate by surgeons. The Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The company is developing MAR01™ for use as a clinical treatment for Critical Limb Ischemia, and plans to initiate additional clinical trials evaluating MAR01™ in cardiovascular disease, and the clinical setting of orthopedics and tissue repair during 2011.

Patient enrollment for the phase I safety study will begin immediately at The Ohio State University Medical Center (as the first clinical site), under the direction of Dr. Michael Go, Assistant Professor of Surgery in the Division
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 23, 2014 ViaDerma, Inc ... company devoted to bringing new products to market, ... , ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... Today, Nerium International, a leader in ... its “Reflect Your Youth” contest, an effort launched to ... difference in their skin since using Nerium’s product line, ... life as a result of their newfound confidence. , ... by Nerium International to inspire conversations focused on the ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2
... Cephalon, Inc.,(Nasdaq: CEPH ) today announced its ... to an Abbreviated New Drug Application (ANDA),submitted to ... Watson,Laboratories, Inc., requesting approval to market and sell ... In its Notice,Letter, Watson alleges that the U.S. ...
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the ... to a record $2.55 billion in the first quarter,of ... translation,increased revenues by 4%, and acquisitions, net of divestitures, ... were $.53 in 2008,versus $.31 in the year-ago period. ...
... Munich, Germany, April 24, 2008 / b3c ... group at Stanford University are working on a project ... are introduced in a statistically expected and controlled ratio ... ,Sloning will utilize its core technology, Slonomics™, a unique ...
Cached Biology Technology:Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 2Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 2Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 5Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 6Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 7Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 8Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 9Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 10Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 11Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 12Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 13Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library 2
(Date:10/29/2014)... pollutants released by unconventional oil and gas production are ... today in the open access journal Environmental Health ... were found. The study is the first to be ... production sites and could be used to supplement official ... from reserves that do not readily flow to the ...
(Date:10/29/2014)... largest study of its kind to date, researchers have ... heighten the risk for autism. Joseph Buxbaum, Ph.D., Icahn ... Mark Daly, Ph.D., Broad Institute of Harvard and MIT, ... from affected children, parents and unrelated people. They identified ... to the risk for autism spectrum disorder (ASD) – ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... New tires allow race cars to take tight turns ... advantages: They are not necessary for basic flight but help ... escape a predator, you don,t have to be fast, you ... world authority on animal behavior, ecology and evolution and the ...
... deliveries and having them at term but before completing ... likely to have a baby with serious complications including ... , UAB researchers, led by Alan T.N. Tita, M.D., ... and Gynecology Division of Maternal-Fetal Medicine, and colleagues reported ...
... remarkable new discovery shows the four-eyed spookfish to be the ... to focus light in its eyes. Professor Julian Partridge ... years of vertebrate evolution, and many thousands of vertebrate species ... have solved the fundamental optical problem faced by all eyes ...
Cached Biology News:Hind wings help butterflies make swift turns to evade predators, study finds 2Repeat C-section before 39 weeks raises risk of neonatal illness 2Spookfish uses mirrors for eyes 2
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: